Ethyl 2-(4-benzyloxycarbonyl-2-oxopiperazino)acetate | 78818-16-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Ethyl 2-(4-benzyloxycarbonyl-2-oxopiperazino)acetate
• 英文别名: benzyl 4-(2-ethoxy-2-oxoethyl)-3-oxopiperazine-1-carboxylate
• CAS: 78818-16-3
• 化学式: C₁₆H₂₀N₂O₅
• 分子量: 320.345
• InChiKey: YYINXQCHRHHYPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  76.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Ethyl 2-(4-benzyloxycarbonyl-2-oxopiperazino)acetate 在 palladium on activated charcoal lithium hydroxide 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 生成 2-[4-Benzylsulfonyl-2-oxopiperazino] acetic acid
  参考文献：
  名称：

  Design, synthesis, and structure–Activity relationships of unsubstituted piperazinone-Based transition state factor Xa inhibitors

  摘要：

  A series of novel transition state factor Xa inhibitors containing a variety, of lactam ring systems as central templates was synthesized in an expedient manner and allowed for a great deal of structural variability. Among them. the piperazinone-based inhibitors were found to be not only active against factor Xa but also selective over thrombin. Optimization of the P4 moiety yielded several potent compounds with IC50 below 1 nM against factor Xa. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01037-5
• 作为产物：
  描述：

  4-Cbz-2-哌嗪酮 、 碘代醋酸乙酯 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 生成 Ethyl 2-(4-benzyloxycarbonyl-2-oxopiperazino)acetate
  参考文献：
  名称：

  Design, synthesis, and structure–Activity relationships of unsubstituted piperazinone-Based transition state factor Xa inhibitors

  摘要：

  A series of novel transition state factor Xa inhibitors containing a variety, of lactam ring systems as central templates was synthesized in an expedient manner and allowed for a great deal of structural variability. Among them. the piperazinone-based inhibitors were found to be not only active against factor Xa but also selective over thrombin. Optimization of the P4 moiety yielded several potent compounds with IC50 below 1 nM against factor Xa. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01037-5

文献信息

• Selective factor Xa inhibitors
  申请人：COR Therapeutics, Inc.

  公开号：US06211183B1

  公开（公告）日：2001-04-03

  Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

  揭示了针对哺乳动物凝血因子Xa具有活性的新化合物、它们的盐和相关组合物。这些化合物在体外或体内对预防或治疗凝血障碍具有用处。
• Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes
  作者：Mukund M. Mehrotra、Julie A. Heath、Jack W. Rose、Mark S. Smyth、Joseph Seroogy、Deborah L. Volkots、Gerd Ruhter、Theo Schotten、Lisa Alaimo、Gary Park、Anjali Pandey、Robert M. Scarborough

  DOI：10.1016/s0960-894x(02)00095-1

  日期：2002.4

  The synthesis and biological activity of analogues containing spiro piperidinylpyridine and pyrrolidinylpyridine templates are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the spiro structures as central template for nonpeptide RGD mimics. (C) 2002 Elsevier Science Ltd. All rights reserved.
• SELECTIVE FACTOR Xa INHIBITORS
  申请人：COR THERAPEUTICS, INC.

  公开号：EP0975625A1

  公开（公告）日：2000-02-02
• US6211183B1
  申请人：——

  公开号：US6211183B1

  公开（公告）日：2001-04-03
• [EN] SELECTIVE FACTOR Xa INHIBITORS<br/>[FR] INHIBITEURS SELECTIFS DU FACTEUR Xa
  申请人：COR THERAPEUTICS, INC.

  公开号：WO1998046591A1

  公开（公告）日：1998-10-22

  (EN) Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful $i(in vitro) or $i(in vivo) for preventing or treating coagulation disorders.(FR) La présente invention concerne des composés, ainsi que certains de leurs sels et certaines de leurs compositions, qui présentent une activité dirigée contre le facteur Xa des mammifères. Ces composés conviennent, in vitro ou in vivo, pour la prévention ou le traitement des troubles de la coagulation.